Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmace…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
ThreeD Capital Announces Disposition of Securities of Avicanna; Announces Acquisition of Securities of AI/ML Innovations ThreeD Capital (IDK.CN) after markets closed on Tuesday said that through a series of transactions e | MMT Newswires | |
Avicanna Inc (AVCNF) Q4 2025 Earnings Call Highlights: Strong Profit Margins and Zero Debt ... Avicanna Inc (AVCNF) reports a 10% increase in gross profit margin and a significant reduction in net loss, while maintaining zero debt and expanding its international presence. | ||
Weekly Roundup on the Cannabis Sector & Psychedelic Sector Key Takeaways; Cannabis Sector Canopy Growth Broadened Australian Medical Lineup with New Spectrum Softgels Decibel Cannabis Saw Strong Revenue Growth in Q3 2025 Despite Posting Higher Losses Avicanna Announced Promising Preclinical Data for New Oral Cannabinoid Delivery Platform SNDL Announced Renewal to Buy Back Up to C$100 Million in Shares Under New Repurchase Program Key […] | MMarket Exclusive | |
Avicanna Reports Positive Pre-Clinical Data For Powder Drug Delivery System, Files For U.S. Patent Avicanna (AVCN.TO) Wednesday announced positive preclinical results and the filing of a U.S. provisi | MMT Newswires | |